吉西他滨联合奥沙利铂治疗胰腺癌的疗效及安全性分析
Efficacy and Safety Analysis of Gemcitabine Combined with Oxaliplatin in the Treatment of Pancreatic Cancer

目的：探讨吉西他滨联合奥沙利铂(GEMOX方案)治疗胰腺癌的临床疗效及安全性。方法：选取2022年1月至2024年12月某三甲医院收治的80例胰腺癌患者，随机分为对照组(吉西他滨单药治疗)和观察组(GEMOX方案)，每组40例。比较两组客观缓解率(ORR)、疾病控制率(DCR)、中位生存期(OS)、无进展生存期(PFS)及不良反应发生率。结果：观察组ORR (35.0% vs. 17.5%)和DCR (72.5% vs. 50.0%)显著高于对照组(P < 0.05)；观察组中位OS (9.8个月vs. 7.2个月)和PFS (6.5个月vs. 4.1个月)显著延长(P < 0.05)；两组主要不良反应为骨髓抑制和神经毒性，观察组III~IV级中性粒细胞减少发生率较高(27.5% vs. 15.0%, P < 0.05)，但总体安全性可控。结论：GEMOX方案可显著提高胰腺癌患者生存获益，不良反应可耐受，具有临床推广价值。
Objective: To investigate the clinical efficacy and safety of gemcitabine combined with oxaliplatin (GEMOX regimen) in the treatment of pancreatic cancer. Methods: Eighty patients with pancreatic cancer admitted to a tertiary hospital from January 2022 to December 2024 were randomly assigned to a control group (gemcitabine monotherapy) and an observation group (GEMOX regimen), with 40 cases in each group. Objective response rate (ORR), disease control rate (DCR), median overall survival (OS), progression-free survival (PFS), and adverse reaction rates were compared between the two groups. Results: The ORR (35.0% vs. 17.5%) and DCR (72.5% vs. 50.0%) in the observation group were significantly higher than those in the control group (P < 0.05). The observation group showed significantly prolonged median OS (9.8 months vs. 7.2 months) and PFS (6.5 months vs. 4.1 months) (P < 0.05). The main adverse reactions in both groups were myelosuppression and neurotoxicity. The incidence of grade III~IV neutropenia was higher in the observation group (27.5% vs. 15.0%, P < 0.05), but the overall safety profile was manageable. Conclusion: The GEMOX regimen significantly improves survival outcomes in pancreatic cancer patients with tolerable adverse reactions, demonstrating valuable clinical applicability.